HALOZYME THERAPEUTICS, INC.: net property, plant and equipment

What this measure means

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.

Selected filing history

Related financial histories

• HALOZYME THERAPEUTICS, INC.: total assets
• HALOZYME THERAPEUTICS, INC.: total liabilities
• HALOZYME THERAPEUTICS, INC.: stockholders equity
• HALOZYME THERAPEUTICS, INC.: cash and cash equivalents
• HALOZYME THERAPEUTICS, INC.: net income or loss
• HALOZYME THERAPEUTICS, INC.: operating cash flow
• HALOZYME THERAPEUTICS, INC.: capital expenditure payments
• HALOZYME THERAPEUTICS, INC.: revenue
• HALOZYME THERAPEUTICS, INC.: contract revenue excluding tax
• HALOZYME THERAPEUTICS, INC.: financing cash flow
• HALOZYME THERAPEUTICS, INC.: investing cash flow
• HALOZYME THERAPEUTICS, INC.: retained earnings or deficit
• HALOZYME THERAPEUTICS, INC.: basic weighted-average shares
• HALOZYME THERAPEUTICS, INC.: diluted weighted-average shares
• HALOZYME THERAPEUTICS, INC.: basic earnings per share
• HALOZYME THERAPEUTICS, INC.: diluted earnings per share
• HALOZYME THERAPEUTICS, INC.: income tax expense or benefit
• HALOZYME THERAPEUTICS, INC.: share-based compensation expense
• HALOZYME THERAPEUTICS, INC.: operating income or loss
• HALOZYME THERAPEUTICS, INC.: current assets
• HALOZYME THERAPEUTICS, INC.: interest expense
• HALOZYME THERAPEUTICS, INC.: current liabilities
• HALOZYME THERAPEUTICS, INC.: current accounts payable
• HALOZYME THERAPEUTICS, INC.: goodwill carrying amount
• HALOZYME THERAPEUTICS, INC.: net finite-lived intangible assets
• HALOZYME THERAPEUTICS, INC.: net current accounts receivable
• HALOZYME THERAPEUTICS, INC.: common-stock repurchase payments
• HALOZYME THERAPEUTICS, INC.: net inventory
• HALOZYME THERAPEUTICS, INC.: selling, general and administrative expense
• HALOZYME THERAPEUTICS, INC.: research and development expense

Inspect the source

Entity

HALOZYME THERAPEUTICS, INC. / CIK 0001159036

Captured

2026-09-19T11:16:42.578Z

SEC response SHA-256

09ca2466c06425bbd1ba706e3a09155b9a42131078735be72a3a1bd471a407ac

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001159036.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))